Spark Therapeutics, Inc. to Host Conference Call on Monday June 13th at 8:30 a.m. to Discuss SPK-9001 Phase 1/2 Data for the Treatment of Hemophilia B Presented at EHA
Initial results of the ongoing Phase 1/2 clinical trial of SPK-9001 will be presented on
The call can be accessed by dialing (855) 851-4526 (domestic) or (720) 634-2901 (international), and entering passcode 27643823. To access a live audio webcast, please visit the “Investors” section at www.sparktx.com.
A replay of the call will be available for one week following the call and can be accessed by dialing (855) 859-2056 (domestic) or (404) 537-3406 (international), and entering passcode 27643823 or also available on our website.
Spark is a gene therapy leader seeking to transform the lives of patients with debilitating genetic diseases by developing one-time, life-altering treatments. Spark’s validated gene therapy platform is being applied to a range of clinical and preclinical programs addressing serious genetic diseases, including inherited retinal dystrophies, hematologic disorders and neurodegenerative diseases. Spark’s most advanced product candidate, SPK-RPE65 (voretigene neparvovec), which has received both breakthrough therapy and orphan product designation, reported positive top-line results from a pivotal Phase 3 clinical trial for the treatment of rare blinding conditions. To learn more, please visit www.sparktx.com.
Stephen W. WebsterChief Financial Officer Spark Therapeutics, Inc. Daniel FagaChief Business Officer Spark Therapeutics, Inc.(855) SPARKTX (1-855-772-7589) Media Contact: Ten Bridge Communications Dan Quinn(781) 475-7974 firstname.lastname@example.org